Recently, Sachs et al. 1 reported intra-familial association of a frame-shift mutation at the extreme 3 0 end of exon 12 of the gene Disrupted in Schizophrenia 1 (DISC1) with schizophrenia and schizoaffective phenotypes. In our own sample, we identified this mutation in none of 655 schizophrenia cases but two of 694 non-psychiatrically screened controls. Our findings suggest that this mutation may not play a major role in influencing susceptibility to psychosis.
DISC1 is located on 1q42.1, a region implicated in linkage studies of schizophrenia, bipolar disorder and schizoaffective disorder. [2] [3] [4] [5] This locus was originally implicated from the study of a Scottish family in which the balanced translocation t(1;11)(q42;q14.3) co-segregated with major mental disorders, the translocation disrupting a gene that was named DISC1. 6 Association studies have also implicated DISC1.
7-10 Sachs et al. 1 reported a frame-shift mutation at the extreme 3 0 end of exon 12 of DISC1 that was identified in three siblings (two with schizophrenia, one with schizoaffective disorder) and their asymptomatic father, but not in 424 control individuals. The frame-shift is caused by a 4 bp deletion of one of two adjacent TCAT tetramers and leads to a truncated protein with nine abnormal amino acids at the C-terminus. To further investigate the potential pathogenic relevance of this mutation we genotyped a schizophrenia case-control sample comprising 1349 individuals.
Six hundred and fifty-five individuals meeting criteria for DSMIV schizophrenia (68% male; mean (s.d.) age 44.5 (14.6) years) and 694 ethnically matched controls (67% males; mean (s.d.) age 41.5 (11.5) years) were genotyped. All subjects were white, unrelated and born in the UK or Ireland. Consensus diagnoses were made by two raters from all available information following a semi-structured interview and examination of case notes. Control individuals were recruited from the UK National Blood Transfusion Service. The blood donors were not assessed psychiatrically but none was taking any form of regular medication. In the UK, blood donors are not remunerated and are not over-represented for indigents or the socially disadvantaged.
The 4 bp deletion genotyping was performed using the Sequenom MassARRAYt system (Sequenom, San Diego, CA, USA) as per the manufacturer's instructions. No schizophrenia individual, but two control individuals were identified as heterozygotes for the 4 bp deletion. These controls were sequenced in both directions using Big-Dye terminator chemistry and an ABI3100 sequencer according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). The presence of the 4 bp deletion was confirmed.
An important issue in interpreting our findings is the fact that our controls were not screened to exclude psychiatric illness and could, therefore, include individuals who have suffered with psychotic illness. Although this has minimal impact on the power of our study, 11 it raises the possibility that the observation of two deletions within our controls could actually reflect occurrences within psychotic individuals -if this were the case, it would support a major pathogenic role of this mutation in psychosis. However, this is an extremely unlikely cause of our findings for the following reasons. First, under the assumption that the lifetime risk of schizophrenia/schizoaffective illness in the UK population is of the order of 2-3%, we would expect a random sample of 700 controls to include about 14-21 individuals who could receive such a lifetime diagnosis. It is extremely unlikely that we would find two deletions in this small number of cases but not in 654 well-characterized schizophrenia cases. Furthermore, our blood donor controls are less likely than members of the UK general population to have experienced schizophrenia/schizoaffective illness because (a) they cannot be taking any medication on a regular basis, and (b) they are unpaid volunteers who have engaged proactively with the UK Blood Transfusion Service.
Sachs et al. 1 interpreted their identification of the deletion as important supportive evidence that DISC1 is a susceptibility gene for schizophrenia and schizoaffective disorder, although they acknowledged that insufficient family members were available definitively to associate this mutation with psychosis. This, together with our finding of the deletion in two out of 694 unrelated non-psychiatrically screened controls but none of 655 schizophrenia cases, suggests that the link between the 4 bp deletion frame-shift mutation with schizophrenia and schizoaffective disorder should be treated with caution. Tryptophan hydroxylase (TPH) is a rate-limiting enzyme in the biosynthesis of 5-HT with two isoforms. TPH1 is mainly expressed in peripheral tissues whereas TPH2 is preferentially expressed in the brain serotonergic neurons from the raphe nuclei. Therefore, molecular alterations of the TPH2 gene (chromosome 12q15) have been proposed as a candidate gene associated with many behavioral phenomena including mood disorders, suicide, personality traits and substance abuse.
Recently, Zhang et al. 1,2 identified a functional (G1463A) single-nucleotide polymorphism (SNP) in the TPH2 gene. This alteration results in substitution of a highly conserved arginine residue at position 441 by a histidine (Arg441His). They demonstrated that the levels of 5-HT were 80% lower in PC-12 cells expressing the Arg441His mutant, indicating a severe loss of the mutant's enzyme function to synthesize 5-HT. They also described nine subjects carrying this functional SNP in a cohort of 87 unipolar major depression patients, all over the age of 60 years and from multiple ethnic groups.
More recently, Blakely et al. 3 pointed out that several groups did not find the variant described by Zhang et al. 2 after studying nearly 5000 patients. [4] [5] [6] To add to this puzzle, DNA from the patients with the G1463A polymorphism were kindly made available by Dr Caron's lab to those groups who confirmed the presence of that SNP. However, these data suggest an association of the G1463A variant with severe depression that is refractory to conventional medication, necessitating electrical convulsive therapy (ECT). 2, 7 Moreover, the elderly nature of the cohort raises the possibility that these traits could be related to late onset depression.
Based on these findings, and considering that replication of genotyping data in populations with ethnically heterogeneous background is essential for the understanding of the importance of the initial report, we investigated exon 11 of the TPH2 gene in samples of patients from a Geriatric Reference Center in Belo Horizonte, Brazil. Our cohort comprised 102 patients (87 females, 15 males, age 62-94 years, the mean age at inclusion was 77.3 years), from many ethnic backgrounds, with the diagnosis of late onset major depression according to the Diagnostic and Statistical Manual-IV and the Geriatric Depression Scale, some of them with severe depression. We also analyzed environmental factors frequently related to depression diagnosis like death, socioeconomical problems, concurrent diseases, physical disabilities, caregiver stress and institutionalization. There were 57 subjects in our control group (34 females, 23 males, all 60 years-old or older, the mean age at inclusion was 67.9 years), without personal or familial history of psychiatric disorders. This study was approved by the local Ethics Committee and all subjects signed an informed consent. After DNA extraction (two independent extractions), exon 11 of the TPH2 gene was amplified by PCR (primers available on request) and directly sequenced (in duplicate, both forward and reverse directions) in an ABI 310 automatic sequencer. We did not find the A-allele (His441) in any of the 102 patients or in the controls. Therefore, our data support the notion that this rare TPH2 variant is also not a major determinant of genetic risk for depression in geriatric patients. The high frequency of the minor allele previously found in a geriatric sample 2 might be the result of population stratification. However, considering the failure to replicate their findings in a large independent sample (over 5000 subjects from different populations) [4] [5] [6] and the frequency of the observation of the His441 variant in the initial sample, including a few homozygotes, 2 possible technical artefacts, other than genotype readings cannot be ruled out.
